ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,213.20
      0.25%
      Dow Jones
      39,118.86
      0.00%
      Brent Oil
      85.505
      0.46%
      Bitcoin
      62,690.01
      0.14%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Galectin Therapeutics Inc (GALT)

      7. Galectin Therapeutics Inc (GALT) News

      GALT

      Galectin Therapeutics (GALT)

      Galectin Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GALT
      DateTimeSourceHeadlineSymbolCompany
      01/05/20237:56AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      01/03/20238:14AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      12/06/20228:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      12/02/20226:15AMTipRanksH.C. Wainwright Sticks to Their Buy Rating for Galectin Therapeutics (GALT)NASDAQ:GALTGalectin Therapeutics Inc
      12/01/202211:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      12/01/20228:27AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      11/29/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of StockholdersNASDAQ:GALTGalectin Therapeutics Inc
      11/28/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development SummitNASDAQ:GALTGalectin Therapeutics Inc
      11/17/202210:39AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      11/15/20224:07PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      11/14/20228:00AMGlobeNewswire Inc.Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business UpdateNASDAQ:GALTGalectin Therapeutics Inc
      11/14/20227:56AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      11/14/20227:51AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GALTGalectin Therapeutics Inc
      11/01/20229:35AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      11/01/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLDNASDAQ:GALTGalectin Therapeutics Inc
      10/17/20228:03AMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GALTGalectin Therapeutics Inc
      10/17/20228:02AMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:GALTGalectin Therapeutics Inc
      10/17/20227:54AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      10/14/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Present in Upcoming ConferencesNASDAQ:GALTGalectin Therapeutics Inc
      10/12/20228:00AMGlobeNewswire Inc.Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck CancerNASDAQ:GALTGalectin Therapeutics Inc
      10/12/20227:51AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GALTGalectin Therapeutics Inc
      10/11/20224:45AMTipRanksH.C. Wainwright Sticks to Its Buy Rating for Galectin Therapeutics (GALT)NASDAQ:GALTGalectin Therapeutics Inc
      10/06/202212:22PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:GALTGalectin Therapeutics Inc
      10/06/20228:00AMGlobeNewswire Inc.Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisNASDAQ:GALTGalectin Therapeutics Inc
      10/03/202211:45AMEdgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:GALTGalectin Therapeutics Inc
      10/03/20229:23AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      09/15/20224:23PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
      09/08/20228:00AMGlobeNewswire Inc.Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022NASDAQ:GALTGalectin Therapeutics Inc
      08/16/20226:25AMTipRanksGalectin Therapeutics (GALT) Gets a Buy from H.C. WainwrightNASDAQ:GALTGalectin Therapeutics Inc
      08/15/20225:47PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GALTGalectin Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:GALT